For decades, Medical Affairs teams have served as the trusted guardians of scientifically accurate communication in the pharmaceutical industry. Today, their rising strategic role and the need to enhance customer experience, are now key reasons why the Medical Affairs function is playing a larger role in external engagements. Evolving regulations, changing market conditions, and a stronger focus on patient-centric care are also prompting closer collaboration between Medical Affairs and Commercial teams.
The Medical Affairs Digital Strategy Council comprises 16 Medical Affairs leaders from a diverse set of pharmaceutical companies with US, EU, and global remits. The Council was formed in 2019 to bring together leaders from the industry to connect, collaborate, and learn from each other and propel Medical Affairs toward a digital future. The focus is to help Medical Affairs organizations embrace technology and innovation through a digital and data-driven model to further unlock growth and maximize the impact across internal and external engagements.
This whitepaper, based on a survey of Council members, explores the cultural transformation underway within Medical Affairs teams as they increasingly engage with their Commercial counterparts. It examines how traditional boundaries—once sharply defined—are giving way to a more integrated, customer and patient focused model.
More than three quarters of the Medical Affairs leaders shared that they are experiencing greater transparency and collaboration with Commercial teams within their organizations. This is a significant shift when compared to just 5 to 10 years ago, when Medical Affairs and Commercial often operated in distinct silos where collaboration between these two functions was viewed with caution, primarily due to compliance concerns and fears of “scientific overreach” by commercial interests. Conversations were often filtered, and joint strategic planning was rare.
Fig 1: Are you seeing greater transparency and collaboration between Medical Affairs and Commercial teams in your respective organizations?
Fast forward to today, and the story is changing. This 78% “Yes” response reflects a broader cultural and operational transformation in the life sciences industry. This transformation is still ongoing, with some organizations pioneering initiatives such as co-led brand teams, and others still struggling with legacy.
So, what might be fuelling this transition? Here are some of the major drivers—though the list isn’t exhaustive:
This shift marks a moment of opportunity and responsibility for the Medical Affairs community. Closer collaboration shouldn’t dilute scientific integrity. Medical Affairs leaders now have a stronger seat at the table, influencing product strategy, shaping stakeholder experiences, and co-creating value with Commercial—while still upholding scientific standards and compliance.
24% of Medical Affairs leaders pointed to “sharing of insights” as the most visible outcome. This suggests that data and knowledge exchange is becoming the foundational layer of cross-functional collaboration. But as Council members pointed out, sharing insights goes beyond mere collection—it’s about validating what truly qualifies as an insight, aligning on it, and then effectively collating and disseminating it. Other signs of integration—like shared infrastructure (20%) and common customer journey maps (20%)—show promising developments. Discussion with the Council members revealed that true collaboration must be operationalized through deliberate design—shared insights, common infrastructure, and joint planning processes are some ways this is beginning to happen.
Fig 2: In your organization, how is collaboration being reflected, if at all?
While structured cross-functional models can successfully align teams, challenges remain, particularly in areas such as joint customer teams and the lack of clarity of roles between Medical Affairs and Commercial teams that create ambiguity. The setup of joint customer teams aims to deliver a seamless customer experience, but often suffers from unclear roles, leading to overlap, mixed messaging, or internal friction. Without well-defined boundaries, even collaborative efforts can result in confusion and inefficiencies.
Internal alignment - Better HCP Engagement - Improved Patient Outcomes

Faster decision-making
Reduced redundancy
Improved lifecycle management
Compliance confidence

Better HCP experience
Better field coordination
Stronger trust and partnership between HCP and Medical Affairs teams

Faster access to therapies
Improved adherence and education
More personalized care
When asked whether Commercial leadership prioritizes transparency and collaboration with Medical Affairs, 67% of Medical Affairs leaders believe the answer is yes. While majority of the Medical Affairs leaders report that Commercial leadership is prioritizing transparency and collaboration with Medical Affairs, discussions reveal that the strength of this commitment often hinges on visible and consistent support from the top.
Examples like joint Commercial and Medical Affairs Town Halls and promoting co-leadership roles demonstrate how leadership can set the tone for integration. However, these initiatives require more than symbolic alignment—they depend on clearly defined roles, mutual accountability, and a shared understanding of success. Furthermore, there is a growing consensus that Medical Affairs must proactively assert its strategic value rather than operate reactively.
Fig 3: Do you believe that greater transparency and collaboration between Medical Affairs and Commercial teams is seen as a priority by the commercial leadership?
This shift calls for not only a change in mindset but also deliberate investments in capability building and communication frameworks. Building skills in business acumen, influencing and communicating in a way that Commercial can understand will be important if Medical wants to improve the prioritization of this collaboration.
This raises important questions for the Medical Affairs community: Are we clearly communicating the value we bring beyond scientific accuracy? Are there consistent KPIs or frameworks that showcase how Medical Affairs efforts contribute to business outcomes? Are we engaging Commercial leadership proactively—or reactively?
For Medical Affairs leaders, this is an opportunity to reflect and recalibrate:
How can we better showcase our strategic contributions aligned to our business goals?
What narratives or proof points resonate most with Commercial stakeholders?
Do we have a seat at the planning table early enough to influence shared objectives?
While momentum is building around Medical Affairs–Commercial collaboration, leaders say the journey is still evolving. In an open-ended poll, Medical Affairs leaders candidly shared the practical hurdles they’ve encountered. Collaboration efforts are often impeded by entrenched ways of working, misaligned incentives, and operational silos. Legacy organizational models, coupled with compliance constraints and disparate infrastructures, make alignment challenging. It’s also noted that demonstrating the impact of collaboration takes time—but it is expected to improve with greater clarity around strategy, shared understanding of objectives and KPIs, and better communication of the overall plan.
Council members emphasized that bridging mindsets is critical. Medical Affairs must learn to operate with more agility and Commercial must appreciate the longer-term value that Medical Affairs brings. It’s important to recognize that it takes time to build trust. Interestingly, the absence of unified SOPs and governance models emerged as both a challenge and an opportunity, making it possible for organizations to co-create new models of collaboration that are tailored, agile, and scalable.
How can organizations move from intent to action? Below is a tactical roadmap to help Medical Affairs and Commercial teams operationalize collaboration and build scalable impact.
Fig 4: How have your team members reacted when being asked to collaborate with colleagues on the Commercial side?
There is a mix of sentiments on the ground: Cautiously optimistic yet positive. While many Medical Affairs leaders report positive experiences collaborating with Commercial teams, there remains an undercurrent of hesitation, largely rooted in the fear of being perceived as commercially biased. This caution underscores a deeper need for cultural evolution—one that organizations must nurture over time. Council members acknowledged that meaningful change must be led intentionally by leadership, not only through vocal support but through sustained action.
To normalize cross-functional collaboration, leaders should offer consistent strategic clarity, reinforce messaging through various internal channels, and establish structured forums that enable open dialogue and shared goal setting. Additionally, organizations should embed proactive change management practices and offer targeted training programs that empower Medical Affairs professionals to build confidence and competence in collaborative roles. These steps, taken together, can foster a culture of trust, reduce resistance, and accelerate the shift toward integrated, patient- and value-centric engagement models.
As the role of Medical Affairs evolves, the expectations from teams are also expanding. They are increasingly expected to act as bridges between the scientific and business worlds. This shift demands new capabilities— such as business acumen and digital fluency—along with behavioural attributes like comfort with ambiguity and cross-functional collaboration.
Council members highlighted the need to update hiring practices and internal training to reflect these new demands. Additionally, there is an urgent need to articulate Medical Affair’s value in business-relevant terms and leverage digital platforms to amplify impact. Moving forward, organizations must prioritize these competencies to enable Medical Affairs to thrive in a hybrid, insight-driven future.
And as AI, automation, and omnichannel become table stakes, CIOs must lead the organization in embracing a tech-forward, compliant, and insight-driven future
Traditional collaboration anchors Medical Affairs and Commercial teams at key milestones—but forward-looking organizations are layering in earlier, data-driven, and experience-focused touchpoints. It’s not about replacing the old with the new but building a seamless continuum of collaboration.
Enhanced collaboration between Medical Affairs and Commercial functions offers a significant opportunity for the pharmaceutical industry—to align scientific excellence with business impact, ultimately improving patient outcomes. As the industry evolves, those who embrace this partnership with intentionality and integrity will lead the future of pharma success.
We thank the members of the Medical Affairs Digital Strategy Council for their active contributions towards this paper:
Mary Alice Dwyer
Vice President, US Synetic Life Sciences | Council Chair
Andrew Fariello
Vice President, Global Medical Capabilities, Oncology, AstraZeneca
Deborah Ebert Long, MD
Senior Vice President, Medical Affairs, CSL
Fran Paradiso-Hardy
Vice President and Head of Medical Communications, Astellas Pharma
Heather Abourjaily
Head of Global Scientific Communications, Stoke Therapeutics
Jennifer Riggins
President, Medical Affairs and Digital, JSR Medical Affairs Consulting, LLC
Calvin Chan
Global Head of Medical Affairs, Insights, Digital, Analytics
Joanne Jani
Head, Global Medical Communications, Regeneron Pharmaceuticals, Inc.
Jung Hyun Lee, PharmD
Sr. Director, Global Medical Content Strategy, AstraZeneca
Manoj Venkiteshwar
Head of Medical Affairs and Professional Education, ZEISS Medical Technology
Robin Winter-Sperry, MD
Medical Affairs Professional Society (MAPS) Director, MAPS Americas Region President
Thierry Aupérin
Vice President, Global Head Scientific Communications, Alnylam Pharmaceuticals
Wendy Kampman, MD
Vice President, Medical Affairs, Medical Information, Technology and Innovation, Vertex Pharmaceuticals
Sarika Sood
Vice President, Medical Engagement-Medical Affairs + HEOR, AbbVie
Michael Cuozzo
Associate Vice President, Medical Information and Content Development, Incyte
Dat Nghiem
Vice President, Head of Medical Analytics and AI, Pfizer